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cream or lotion into the surface layer of skin Stratum Corneum 
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Niacin is delivered to blood capillary cells 
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of oxygen in the dermis where it supports 
energy metabolism of dermal fibroblasts 
The increased oxygen in the dermis diffuses 
into the epidermis where it supports energy 
metabolism in epidermal keratinocytes 
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METHODS AND COMPOSITIONS USEFUL 
IN ENHANCING OXYGEN DELIVERY TO 
CELLS 
RELATED APPLICATION 
This application claims priority of provisional application 
Ser. No. 60/197,227, ?led Apr. 14, 2000, incorporated by 
reference. 
FIELD OF THE INVENTION 
This invention relates to methods that are useful in 
improving the delivery of oxygen to tissues and organs, such 
as skin. Therapeutic uses of the method are disclosed as 
Well. 
BACKGROUND AND PRIOR ART 
The skin plays multiple roles in protection from environ 
mental insults. Environmental exposure results in the pro 
gressive deterioration of skin that is initially cosmetic but 
can lead to end stage diseases such as actinic keratosis and 
skin cancer. Hereinafter, While the skin Will be discussed 
speci?cally, it is to be understood that the remarks are 
applicable to organs and tissues in general. 
Health of skin, as Well as other tissues and organs, is 
dependent upon supplies of many essential nutrients to 
cellular components Which are a part thereof, oxygen in 
particular, as Well as the ef?cient removal of Waste products 
such as carbon dioxide, and other metabolic end products. 
An optimal supply of oxygen is required in order to support 
metabolic pathWays Which inter alia, support the cellular 
mechanisms that lead to resistance of skin deterioration. 
The delivery of oxygen to skin via blood circulation is 
distal to delivery to most other organs. Further, the upper 
most living layer of skin, i.e., the “epidermis,” is non 
vascular. This leaves the upper layers of skin at high risk of 
receiving insuf?cient oxygen. 
Skin is a complex organ system, consisting of multiple 
layers. The uppermost, or “stratum corneum” layer, consists 
of non-living material derived primarily from the terminal 
differentiation of epidermal keratinocytes, and provides a 
protective barrier for the underlying components of skin. 
The epidermis contains a number of cell types, although 
keratinocytes are the major cell type. Dermal ?broblasts are 
embedded Within a matrix comprised of collagen, elastin, 
proteoglycans, and other extracellular matrix molecules. 
Blood capillaries are found in the dermis, but the epidermis 
is non-vascular. 
As people age, progressively deleterious changes in skin 
appearance occur. The initial changes are the loss of smooth 
skin texture and the appearance of age spots, folloWed by 
changes in elasticity that lead to the appearance of skin 
Wrinkles. The age at Which these changes appear and the rate 
at Which one stage progresses to the next varies greatly from 
individual to individual. During the normal aging process, 
both the epidermis and dermis become thinner With a loss of 
cell numbers and connective tissue, leading to the appear 
ance of ?ne Wrinkles. Ultraviolet (UV) irradiation from the 
sun causes photodamage that accelerates skin deterioration. 
In contrast to the thinning observed in sun-protected skin, 
photodamaged skin has a thickened and rough appearance 
With an increase in deeper skin Wrinkling Which occurs in 
dermal tissue. Photodamage also causes end-stage skin 
deterioration including pre-malignant lesions termed actinic 
keratosis and skin cancer. 
Compelling evidence noW indicates that oxidative stress, 
de?ned as an abnormal accumulation of reactive oxygen 
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species (ROS hereafter) is involved in the pathophysiology 
of skin deterioration. ROS include, inter alia, superoxides, 
the hydroxyl radical, hydrogen peroxide, singlet oxygen, 
nitric oxide, peroxynitrite, and hypochlorite. See, e.g., 
Simonian, et al., Ann. Rev. Pharmacol. Toxicol. 36:83—106 
(1996), incorporated by reference. All cells are exposed to 
ROS during the normal course of energy metabolism, via 
environmental exposure and/or immune surveillance. While 
ROS are involved in normal cell signaling pathWays, eleva 
tion of ROS during oxidative stress disrupts signaling 
pathWays, often resulting in cell death by apoptosis or 
necrosis. Thus, it is likely that ROS are involved in the 
decrease in cell number observed over time, even in sun 
protected skin. 
Exposure to the ultraviolet rays of sunlight is a major 
source of skin oxidative stress. TWo major targets for dam 
age by ROS in skin are DNA and protein. DNA damage is 
of particular interest in that unrepaired damage can lead to 
the loss of skin cells and to altered functioning of cells that 
survive genotoxic stress. 
While some changes in skin during aging can not be 
avoided, much skin deterioration at an early age is avoid 
able. Skin cells contain a number of protective mechanisms 
for the prevention and repair of ROS damage to DNA and 
protein. For example, a number of intracellular molecules, 
including glutathione and the antioxidant vitamins C and E 
play key roles in scavenging ROS before they can react With 
cellular macromolecules. Indeed, the antioxidant vitamins 
have already found application in the prevention of skin 
deterioration, as they are components of many skin creams. 
Also, cells contain complex mechanisms for the mainte 
nance of genomic integrity. Of particular interest herein is 
the accumulating evidence for the involvement of DNA 
repair mechanisms in maintaining the genomic integrity of 
organs and tissues subjected to genotoxic stress caused by, 
e.g., ROS, including skin. 
The delivery of oxygen is important for proper mainte 
nance of cell energy metabolic pathWays, Which in turn is 
important for alleviating the problems discussed herein. It is 
desirable to have a method available by Which oxygen 
delivery to a tissue or organ, such as the skin, can be 
improved. Hence, one object of the invention is a method for 
improving delivery of oxygen to tissues and organs, such as 
skin. Yet a further aspect of the invention are compositions 
useful in achieving this goal. Still a further aspect of the 
invention is the treatment of conditions Where improved 
oxygenation is called for, via application of the methods and 
compositions of the invention. 
HoW these aspects of the invention are met Will be seen 
from the disclosure Which folloWs. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 depicts the skin, in cross section, in combination 
With an illustration of the delivery system of the invention. 
FIG. 2 depicts data obtained in accordance With the 
invention, via the use of a transcutaneous oxygen monitor. 
FIG. 3 shoWs results from a further experiment, using the 
transcutaneous oxygen monitor. 
FIG. 4 shoWs data from an experiment shoWing that 
niacin esters are converted to niacin in order to improve skin 
oxygenation. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The invention described herein involved various formu 
lations designed to enhance delivery of oxygen to tissues 
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and organs, such as the skin. The compositions are formu 
lated so as to partition rapidly into a layer, such as the 
stratum corneum layer of the skin, at a rate Which permits 
sustained delivery of an active agent or agents to, e.g., the 
epidermis, in a sustained fashion and at a concentration 
Which provokes capillary dilation. As a result of capillary 
dilation, blood ?oW increases, thereby increasing oxygen 
tension in the dermis Which in turn supports both energy 
metabolism in epidermal ?broblasts, and epidermal kerati 
nocytes When the skin is involved, and other parallel cell 
types When other tissues and/or organs are involved. 
The highly lipophilic nature of the stratum corneum 
dictates that the desired oxygen enhancing agent must be 
sufficiently lipophilic to effectively partition into the stratum 
corneum from the donor compartment, Which may be, e.g., 
a skin cream or lotion. This necessitates the preparation of 
a distinct lipophilic agent, such as those described in more 
detail infra. Diffusion from the stratum corneum into the 
epidermis also requires that the agent should be suf?ciently 
lipophilic to rapidly partition from the cream or lotion into 
the stratum corneum. Niacin esters are exempli?ed herein. 
Lipophilic derivatives of niacin esters can be prepared, and 
these are converted into active niacin esters folloWing dif 
fusion out of the stratum corneum into the epidermis; 
hoWever, other materials could also be used. The lipophi 
licity of the agent should alloW it to be formulated in, e.g., 
skin cream or lotion and the ester linkage should be very 
stable in these formulations to, e.g., chemical hydrolysis 
under aqueous conditions. 
The experiments Which folloW set forth the invention in 
greater detail, but should not be construed as limiting the 
invention in any Way. 
EXAMPLE 1 
Nicotinic acid esters Were synthesiZed in accordance With 
Ser. No. 09/452,617, ?led Dec. 1, 1999, incorporated by 
reference. In brief, nicotinoyl chloride Was combined With 
triethylamine (TEA), dimethylaminopyridine (DMAP), and 
various alkyl alcohols, under nitrogen. Esters resulting from 
the synthesis Were separated via silica gel column 
chromatography, and converted to HCl salts for further 
puri?cation, using standard methods. The purity Was con 
?rmed via thin layer chromatography, and 1H-NMR. 
The Pod/W values for these compounds Were determined in 
accordance With Harnisch, et al., J. Chromatog. 
282:315-332 (1983), incorporated by reference. This refer 
ence also describes determination of “log P” values, 
described infra. 
EXAMPLE 2 
This example details the ?rst of tWo sets of experiments 
designed to determine the vasodilation effect of alkyl niacin 
esters. Formulations Were prepared by combining the alkyl 
esters referred to supra in a skin lotion, at 0.1% and 1.0% 
concentrations. The lotions Were applied topically to the skin 
of human volunteers on the anterior surface of a forearm. 
Vasodilation Was observed visually, i.e., by observing blush 
ing at the site of application, or lack thereof. Both onset and 
duration of vasodilation Were measured. 
The results for the esters tested are set forth in Table 1, 
Which folloWs. This table includes lipophilicity of the tested 
compounds, in log P values, folloWing Harnisch, et al., 
supra, incorporated by reference, as Well as the results of 
visual observation. 
It Will be seen that small chain alkyl esters, i.e., those With 
8 carbon atoms or less in the alkyl chain, caused vasodilation 
10 
15 
20 
25 
30 
35 
45 
50 
55 
60 
65 
4 
at concentrations as loW as 0.1%, While C9 and C10 alkyl 
esters caused vasodilation at 1.0% formulations. The longer 
chain esters, i.e., those at C12 or higher, did not provoke 
vasodilation at either concentration. 
The onset and duration of vasodilation Was determined, 
again by visual determination, for C2, C6, and C8 alkyl 
esters. Results are set forth in Table 2. Note that the log P 
values provided for the C9 and C11 compounds are derived 
from a plot of experimentally determined values for other 
compounds. The C8 compound provided the longest effect. 
Thus, niacin esters With log P values of less than 6.0 are 
preferred. Most preferred are esters With log P values in the 
range of from about 4.5 to about 5.5. 
TABLE 1 
Properties of Niacin Esters 
Alkyl Carbon Vasodilation at 
Chain Length Log P Value" 0.1% 1.0% 
1 carbon 0.84 Yes Yes 
2 carbons 1.3 Yes Yes 
4 carbons 2.4 Yes Yes 
6 carbons 3.5 Yes Yes 
8 carbons 4.8 Yes Yes 
9 carbons 5.0" No Yes 
10 carbons 5.8 No Yes 
11 carbons 6.0" No Slight 
12 carbons 6.6 No No 
13 carbons 7.5 No No 
14 carbons 7.6 No No 
15 carbons 8.3 No No 
16 carbons 9.2 No No 
18 carbons 9.7 No No 
TABLE 2 
Vasodilation Properties of Selected Niacin Esters 
Vasodilation Effect at 0.1% 
Niacin Ester Onset Duration 
Ethyl niacin 5-10 min 30-45 min 
Hexyl niacin 10-15 min 60-90 min 
Octyl niacin 10-20 min 240-360 min 
EXAMPLE 3 
The experiments reported in Table 1 reveal compounds 
that provide sustained vasodilation folloWing topical appli 
cation; hoWever, they do not indicate Whether the vasodila 
tion effect is accompanied by an increased release of oxygen 
into the skin tissue. To examine this issue, the oxygen 
content of skin to Which the octyl ester discussed supra Was 
determined directly, using a transcutaneous oxygen monitor. 
The 1% formulation of the octyl ester Was applied to skin for 
30 minutes. After this thirty minute period, the skin Was 
cleaned With soap and Water, Wiped With an alcohol sWab, 
and a drop of deioniZed Water Was placed on the sensor 
surface before its attachment to the anterior surface of the 
volunteers’ forearms. The transcutaneous values Were 
recorded constantly, and stored by the instrument. The 
monitor measures relative oxygen content, because the tem 
perature at Which the monitor operates does impact the 
oxygen permeability of the stratum corneum. See, e.g., 
Martin, Resp. Care 35:577-589 (1990), incorporated by 
reference. The sensor Was calibrated at 4 hour intervals, or 
Whenever the sensor temperature Was changed. 
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The results of one set of experiments are presented in FIG. 
2. The monitor Was operated at a temperature of 40° C. 
Values are given for both a control, and the formulation 
described herein. 
The ?rst, high value is representative of oxygen tension of 
air in the monitor probe at the time of application, and then 
drops rapidly to a very loW value, demonstrating loW skin 
oxygen content. This Was folloWed by an increase and a 
plateau, Which is attributed to the effect of simply operating 
the monitor at 40° C. The depicted results then shoW a 
sustained increase in skin oxygen as a result of application 
of the niacin ester. Comparison of the results for the control 
and the test compound shoW a clear increase in the amount 
of oxygen being delivered to the capillaries. 
In a folloW-up experiment, the monitor Was operated at 
38° C., and both O2 and CO2 Were measured, With a 
combined transcutaneous oxygen and CO2 monitor. FIG. 3 
presents these results. The control is represented by the 
dotted line. The results shoW a sustained increase in skin 
oxygen content, and a decrease in CO2 content as a result of 
the application of the niacin ester. The latter result indicates 
that the topical application is also enhancing removal of 
metabolic products. While the results of skin oxygen and 
CO2 measurements are consistent With the observed vasodi 
lation reported in Table 1, observation of vasodilation alone 
does not necessarily indicate an increased release of oxygen 
into the skin tissue; hoWever, the results disclosed in FIGS. 
2 and 3 demonstrate that application of the niacin esters 
effects both increased blood flow into skin and increased 
release of oxygen into the skin. 
EXAMPLE 4 
Previous Work by Sugibayashi, et al., J. Controlled 
Release 62:201—208 (1999) has shoWn that, With respect to 
skin, there is little or no esterase activity in the stratum 
corneum, the epidermis has highest activity, and the dermis 
has reduced activity relative to the epidermis. As such, 
experiments Were undertaken to determine if esters require 
conversion to other molecules in order to provoke oxygen 
ation. An experiment demonstrating that niacin esters 
require conversion to niacin in order to achieve skin oxy 
genation is shoWn in FIG. 4. Parallel experiments Were 
carried out using 0.1% octyl niacin ester lotion, and a lotion 
containing octyl niacin ester (0.1%), and 0.1% butyl ben 
Zoate. Butyl benZoate has a log P value of 3.5, as compared 
to a value of 4.8 for the octyl ester, suggesting faster 
partitioning into the epidermis. The presence of the inactive 
ester, i.e., butyl benZoate, blocked the increase in oxygen 
content, demonstrating that the conversion of niacin ester to 
niacin is required. This also shoWs that inactive co-esters can 
be used the modulate the oxygenation effect. 
Oxygen content Was measured in the same Way as is 
described, supra, or using other techniques knoWn to the art. 
The foregoing examples describe the invention, Which 
relates to methods and compositions for increasing oxygen 
delivery to cells. Brie?y, these require the use of a derivative 
of a vasodilator compound, Wherein the derivative has a 
structure such that improved permeation of the vasodilator 
compound is achieved. In the case of niacin, esters are 
preferred. Any ester Which is a substrate for an indigenous 
esterase may be used, and is a part of the invention. 
Especially preferred is the octyl ester of niacin. Especially 
preferred are esters Which have log P values, as described 
supra, Which are loWer than about 6.0, more preferably from 
about 4.5 to about 5.5. 
Also a part of the invention is the use of esteri?ed, alcohol 
analogs of nicotinic acids, Wherein the ester group contains 
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from 6 to 12 carbon atoms, preferably 8 to 10, and most 
preferably 8 carbon atoms. Such molecules also function in 
the Way the niacin esters function. Alcohol analogs of niacin 
cause vasodilation, and the ester derivatives act in the same 
Way as the ester described supra. 
“Derivative” as used herein refers to any chemical modi 
?cation of the base, vasodilator compound Which results in 
a molecule With the permeation qualities described supra, 
e.g., a log P values beloW about 6.0 Esters of compounds 
such as acid and alcohol esters, are exemplary of such 
molecules, but are not the only such compounds. 
The active ingredient may be applied in any of the 
standard, topical formulations Well knoWn to the art, such as 
creams, lotions, salves, balms, roll-on sticks, shampoos, 
Washes, suppositories, and so forth. The amount of the active 
composition in the formulation Will vary. Preferably, 
hoWever, the concentration Will range from about 0.05% to 
about 5.0% by Weight. Most preferably, the formulation is 
one Where the ester concentration ranges from about 0.1% 
by Weight to about 1.0% by Weight. 
These formulations are useful in the treatment of condi 
tions Where improved or enhanced oxygenation of tissue is 
desirable. Such conditions Will be Well knoWn to the skilled 
artisan. 
Enhanced oxygenation, as discussed supra, enhances 
other processes Within the organ. Hence, a further feature of 
the invention is the use of the formulations, described supra, 
in combination With materials such as nutrients, 
micronutrients, pharmaceutical agents, and other materials 
Where enhanced oxygen delivery Will improve the efficacy 
of the additional material. Of particular interest are com 
pounds and formulations, such as nicotinic acid esters Which 
have log P values in the range described, supra. The art is 
familiar With hoW to determine the log P values, as Was 
shoWn via the citation to, e.g., Harnisch, et al., supra and 
need not be reiterated here. Similarly, a methodology is set 
forth herein Which shoWs the skilled artisan hoW to deter 
mine if a particular compound, such as a nicotinic acid ester, 
increases and/or improves oxygenation. Alkyl esters of 
nicotinic acid have been described herein; hoWever, other 
materials, including other nicotinic acid esters can be used 
as Well, as long as they satisfy the criteria that are adduced 
herein. 
Other aspects of the invention Will be clear to the skilled 
artisan and need not be set forth herein. 
The terms and expressions Which have been employed are 
used as terms of description and not of limitation, and there 
is no intention in the use of such terms and expressions of 
excluding any equivalents of the features shoWn and 
described or portions thereof, it being recogniZed that vari 
ous modi?cations are possible Within the scope of the 
invention. 
We claim: 
1. Amethod for enhancing delivery of oxygen to a tissue, 
comprising administering to said tissue a nicotinic acid alkyl 
ester containing composition, Wherein the alkyl group of 
said nicotinic acid alkyl ester consists of from 8 to 10 carbon 
atoms, Wherein said composition contains from about 0.05 % 
to about 5.0% by Weight of said compound, in an amount 
sufficient to enhance oxygen delivery to said tissue. 
2. The method of claim 1, Wherein said nicotinic acid 
alkyl ester is applied topically. 
3. The method of claim 1, Wherein said tissue is skin. 
4. The method of claim 1, Wherein said nicotinic acid 
alkyl ester is nicotinic acid octyl ester. 
5. The method of claim 1, Wherein said composition 
contains from about 0.1% to about 1% by Weight of said 
compound. 
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6. The method of claim 1, wherein said composition is a 
cream, a lotion, a salve, a balm, a roll-on stick, a Wash, or 
a suppository. 
7. The method of claim 1, Wherein said composition 
further comprises butyl benZoate in an amount sufficient to 
modulate oxygenation by inhibiting conversion of said nico 
tinic acid alkyl ester to nicotinic acid. 
8. The method of claim 1, Wherein said alkyl group of said 
nicotinic acid alkyl ester consists of 8 carbon atoms. 
5 
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9. The method of claim 1, Wherein said alkyl group of said 
nicotinic acid alkyl ester consists of 9 carbon atoms. 
10. The method of claim 1, Wherein said alkyl group of 
said nicotinic acid alkyl ester consists of 10 carbon atoms. 
11. The method of claim 1, Wherein said composition 
enhances delivery of oXygen for at least 4 hours. 
